Highest-materiality recent filing
Director Andrew J. Ritter resigns from Nordicus Partners board
Resigned effective July 7, 2026, to pursue other business opportunities.
Nordicus Partners issues 201,500 restricted shares at $2.75 per share to five investors
Issued 201,500 restricted shares at $2.75/share to five private investors in March-April 2026; offering closed June 23, 2026.
Nordicus Partners establishes board committees, appoints members and chairs
Audit Committee: Kim Mücke (Chair, financial expert), Andrew J. Ritter, Peter Severin.
Nordicus Partners raises ~$360k via issuance of 131k restricted shares at $2.75/share
Issued 131,000 restricted shares to ten private investors at $2.75 per share.
Nordicus Partners closes private placement of 416,000 shares at $2.75 each
Issued 416,000 restricted common shares to eight private investors at $2.75/share.
Nordicus Partners closes private placement of 1,057,500 shares at $1.90 to 54 investors
Issued 1,057,500 restricted common shares at $1.90 per share from July to September 2025; closed Sept 18, 2025.
Nordicus Partners furnishes independent valuations for Orocidin and Bio-Convert subsidiaries
Stanton Park Advisors LLC prepared valuation reports for Orocidin's QR-01 and Bio-Convert's QR-02 as of June 30, 2025.
Nordicus appoints three new directors after Keller resignation
Henrik Keller resigned from Board effective August 7, 2025 to pursue other interests.
Nordicus Partners issues 35,000 restricted shares at $4.00 in private placement
Sold 35,000 restricted common shares on June 16, 2025 at $4.00/share, raising $140,000.
Nordicus Partners approves one-year CEO and CFO pay packages of $360K and $120K
CEO Henrik Rouf's amended employment agreement provides base salary of $360,000/year for one year starting July 1, 2025.
Nordicus Partners issues 54,000 restricted shares at $5.00 each in private placement
Issued 54,000 restricted shares of common stock at $5.00/share to two private investors in April and May 2025.
Nordicus Partners to present on Bio-Convert A/S; no new financial data in filing
Presentation to analysts and investors regarding wholly owned subsidiary Bio-Convert A/S on or after April 1, 2025.
Nordicus Partners furnishes investor presentation on Orocidin A/S subsidiary
Company filed Regulation FD disclosure to provide a presentation about its wholly owned subsidiary Orocidin A/S.
Nordicus Partners grants warrant to buy 1M shares at $8.91 floor to Danish investor
Issued warrant to purchase 1,000,000 shares of common stock to GK Partners ApS on December 30, 2024.
Nordicus Partners files 8-K to furnish investor presentation; no details provided
Company furnishes a presentation to analysts and investors on or after January 2, 2025.
Consulting agreement with Harbor Access LLC for $8,000/month, term through November 30, 2025.
Nordicus Partners acquires 100% of Bio-Convert ApS for 12M restricted shares
Acquired 100% of Danish clinical-stage biopharma Bio-Convert ApS on Nov 12, 2024.
Nordicus acquires remaining ~5% of Orocidin, making it wholly owned subsidiary
Acquired 29,663 Orocidin shares (5.34% of outstanding) for 200,000 restricted common shares.
Nordicus appoints Peter Severin as chairman after Christian Hill-Madsen resigns
Christian Hill-Madsen resigned from the board effective June 3, 2024; will remain Chairman of Orocidin A/S (95% owned by Nordicus).
Nordicus acquires 95% of Orocidin A/S for $38M in stock, enters periodontitis market
Acquired 525,597 Orocidin shares (95% stake) from 11 shareholders for 38M restricted common shares.
Nordicus Partners acquires 5M Myson shares in exchange for 2.5M restricted shares
Acquired 5,000,000 restricted shares of Myson, Inc. common stock from GK Partners ApS.
Nordicus Partners replaces board member Tom Glasesner Larsen with Henrik Keller on June 9, 2023
Tom Glasesner Larsen resigned from the board on June 9, 2023.
Nordicus Partners terminates auditor BF Borgers, appoints Fruci & Associates
Terminated BF Borgers CPA PC as independent auditor in May 2023; engaged Fruci & Associates II, PLLC as new auditor.
EKIMAS Corp renames to Nordicus Partners, ticker changes to NORD
Certificate of amendment filed with Delaware Secretary of State on May 13, 2023, changing name to Nordicus Partners Corporation.
EKIMAS enters CEO employment and CFO consulting agreements
CEO Henrik Rouf employment agreement: $72,000/year base salary, one-year term starting April 1, 2023.
EKIMAS acquires Nordicus Partners in stock-for-stock deal, exits shell company status
Acquired 100% of Nordicus Partners A/S for 2,500,000 shares of EKIMAS common stock.
EKIMAS issues warrants to purchase 750k shares to consultant and CEO at $1.00
Issued warrants to purchase 500,000 shares to David Volpe for consulting services.
EKIMAS borrows $40K via demand promissory note at 3% interest, maturing June 30, 2023
Principal amount of $40,000; interest at 3% per annum; maturity June 30, 2023.
Former auditor Liggett & Webb notified EKIMAS on Oct 7, 2022 it would no longer offer audit services.
EKIMAS issues 6M-share warrant at $1 (20% discount) to GK Partners ApS; expires Dec 2023
Warrant to purchase 6,000,000 shares of common stock at $1.00 per share, ~20% below market price.
EKIMAS completes stock sale to Reddington; 90% ownership after reverse split
Reddington acquired 51.8% at first close on Oct. 12, 2021, then 90% after second tranche and 1-for-50 reverse split on Mar. 11, 2022.
Reddington Partners acquires 51.8% of EKIMAS; CEO Adams resigns, Yankowitz appointed
Reddington Partners acquired 51.8% ownership (25.57M shares) on Oct 12, 2021, becoming majority stockholder.
EKIMAS Corporation dismisses auditor RBSM LLP, appoints Liggett & Webb P.A.
Dismissed RBSM LLP as independent auditor on Aug 24, 2021, effective Aug 26.
On July 7, 2026, Andrew J. Ritter resigned from the Board of Directors of Nordicus Partners Corporation (the “Company”), effective immediately, to pursue other time-consuming business opportunities.
and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors.
Effective June 3, 2024, Christian Hill-Madsen resigned from the Board of Directors of Nordicus Partners Corporation (the “Company”), and the remaining Board members appointed Peter Severin as his replacement and as Chairman of the Board of Directors.
On June 9, 2023, Tom Glasesner Larsen resigned from the Company’s board of directors, and the remaining board members appointed Henrik Keller as his replacement.
On June 9, 2023, Tom Glasesner Larsen resigned from the Company’s board of directors, and the remaining board members appointed Henrik Keller as his replacement.
Bennett J. Yankowitz was appointed as the Company's chief executive officer and sole director.
Michael F. Adams resigned as the chief executive officer and sole director of the Company
Max materiality 0.90 · Median 0.35 · Most common event other_material